Search Results - "Stepan, D.E."

994O - Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

“…LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. PEMBRO is an anti-PD-1 antibody. We report final results of a cohort of patients…”
Get full text

Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis by Lee, C.-H., Shah, A.Y., Makker, V., Taylor, M.H., Shaffer, D., Hsieh, J.J., Cohn, A.L., DiSimone, C., Marin, A Pinto, Rasco, D.W., Ribe, S.G., Richards, D.A., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Perini, R.F., Motzer, R.J.

Get full text

Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

Get full text

1187PD - Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis by Lee, C.-H., Shah, A.Y., Makker, V., Taylor, M.H., Shaffer, D., Hsieh, J.J., Cohn, A.L., DiSimone, C., Marin, A Pinto, Rasco, D.W., Ribe, S.G., Richards, D.A., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Perini, R.F., Motzer, R.J.

“…Lenvatinib (LEN) is a multikinase VEGFR inhibitor approved for use in combination with everolimus to treat advanced RCC after prior VEGF-targeted therapy…”
Get full text